Office of Commercialization and Economic Development
Office of Technology Commercialization

Early breast cancer screening method by differentiating malignant from benign lesions

Technology #20-0104

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Caterina Gallippi
Managed By
Matthew Howe
Commercialization Manager 919.966.3929
Patent Protection
Provisional Patent Application Filed

Current ultrasound-based systems are not able to differentiate between malignant or benign breast cancer, which is an important aspect of early breast cancer screening. A method has been developed combining acoustic radiation force-based ultrasound and measurement of tissue anisotropy to identify malignant breast cancer. Several viscoelastic characteristics are measured in the lesion and surrounding tissue (elasticity, viscosity, displacement, etc.), to estimate anisotropy, and identify the malignant tissue. 21 breast cancer patients have been screened using this method and malignant or benign lesions were correctly identified 100% of the time for each patient.

Related Publications: